Freiburg Im Breisgau

• GenePHIT: A study to learn more about how well a new gene therapy (AB-1002) works and its safety in participants with congestive heart failu … Ended recruitment
  2024-510581-17-00 4 2024-11-05 Adult subjects with New York Heart Association (NYHA) Class III conges
• Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018 Ended recruitment
  2022-501457-37-00 5 2024-10-28 Myeloid Leukemia in Children with Down Syndrome
• INCA34176-254: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ru … Ended recruitment
  2022-502168-19-00 4 2024-10-22 chronic graft-versus-host disease
• REIMAGINE 5: A research study to see how much CagriSema (1.0 mg once weekly) lowers blood sugar and body weight compared to tirzepatide (5 m … Ended recruitment
  2023-509600-15-00 5 2024-10-18 Type 2 Diabetes
• Frontline Asciminib combination in chronic phase CML Ended recruitment
  2024-516212-24-00 4 2024-10-08 Chronic Myeloid Leukemia
• A study to learn how bimekizumab works in people with moderate to severe plaque psoriasis. Ended recruitment
  2023-506333-29-00 11 2024-10-01 Moderate to Severe Plaque Psoriasis
• A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, … Ended recruitment
  2023-505739-12-01 5 2024-09-30 Chronic Inducible Urticaria (CINDU)
• A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus Ended recruitment
  2023-503692-24-00 5 2024-09-25 Cutaneous Lupus Erythematosus
• An open-label randomized trial of zanidatamab for advanced HER2positive biliary tract cancer Ended recruitment
  2023-508219-21-00 5 2024-09-12 BTC - Biliary Tract Cancer
• A Study to Evaluate the Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Ended recruitment
  2024-511260-84-00 4 2024-09-03 Atopic Dermatitis
• ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended recruitment
  2023-506876-28-00 5 2024-08-01 The medical condition we are investigating is type 1 AMI (STEMI and NS
• A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended recruitment
  2023-503923-24-00 5 2024-07-22 Sjögren’s Syndrome With Moderate-toSevere Symptom State
• MTR² Ended recruitment
  2022-502790-42-00 4 2024-06-24 Primary Central Nervous Lymphoma (PCNSL)
• A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot … Ended recruitment
  2023-506668-15-00 5 2024-06-17 Relapsed or Refractory Multiple Myeloma (RRMM)
• A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participan … Ended recruitment
  2023-503666-23-00 5 2024-06-07 Neovascular age-related macular degeneration
• Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Ended recruitment
  2022-500571-32-00 4 2024-05-15 Early-Stage Unfavorable Classical Hodgkin Lymphoma
• A clinical study of people with HIV-1 who have not taken antiretroviral therapy, one group will start treatment with a combination of doravi … Ended recruitment
  2022-502099-22-01 5 2024-04-29 HIV-1 Infection
• TRAP-BTC Efficacy and safety of GemCis plus Trastuzumab plus Pembrolizumab in previously untreated HER2-positive biliary tract cancer Ended recruitment
  2023-505722-33-00 4 2024-04-15 cholangiocarcinoma or gallbladder carcinoma
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit … Ended recruitment
  2023-505928-59-00 5 2024-04-15 Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
• ATHENA: A research study looking into how ziltivekimab works compared to placebo in people with heart failure and inflammation Ended recruitment
  2023-506988-34-00 5 2024-03-27 Heart failure with mildly reduced or preserved ejection fraction and s
• 52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co … Ended recruitment
  2022-502161-19-00 5 2024-03-12 Chronic Spontaneous Urticaria
• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+ … Ended recruitment
  2024-514458-61-01 4 2024-02-05 HER2+ early breast cancer
• A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended recruitment
  2022-502442-27-00 5 2024-01-08 Obesity
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm … Ended recruitment
  2023-505120-59-00 5 2023-12-19 Moderate to Severe Plaque Psoriasis

Showing 265–288 of 485 trials